

# PUBLICATIONS

Oncologie Moléculaire

1993 - 2015

Last update: 2015-05-12



1. Altmeyer A., Josset E., Denis J.M., Gueulette J., Slabbert J., Mutter D., Noël G., Bischoff P. **The mTOR inhibitor RAD001 augments radiation-induced growth inhibition in a hepatocellular cell line by increasing autophagy.** *Int J Oncol* 2012;41:1381-6.
2. Altmeyer A., Ignat M., Denis JM., Messaddeq N., Gueulette J., Mutter D., Bischoff P. **Cell death detection after high-LET irradiation in an orthotopic human hepatocellular carcinoma.** *In Vivo* 2012
3. Altmeyer A., Jung A.C., Ignat M., Benzina S., Denis J.M., Gueulette J., Noël G., Mutter D., Bischoff P. **Pharmacological enhancement of autophagy induced in a hepatocellular carcinoma cell line by high-LET radiation.** *Anticancer Research* 2010;30:303-310.
4. Lapouge G., Millon R., Muller D., Abecassis J., Eber M., Bergerat J.P., Klein-soyer C. **Cisplatin-induced genes as potential markers for thyroid cancer.** *Cell Mol Life Sci* 2005;62:53-64.
5. Fischer B., Benzina S., Jeannequin P., Dufour P., Bergerat J.P., Denis J.M., Gueulette J., Bischoff P.L. **Fast neutrons induced apoptosis is Fas-independent in lymphobalstoid cells.** *Biochem Biophys Res Commun* 2005;334:533-42.
6. Kurtz J.E., Dufour P., Duclos B., Bergerat J.P., Exinger F. **Saccharomyces cerevisiae: An efficient tool and model system for anticancer research.** *Bull Cancer* 2004;91:133-9.
7. Fischer B., Benzina S., Ganansia-Leymarie V., Denis J.M., Bergerat J.P., Dufour P., Gueulette J., Bischoff P. **Cisplatin enhances the cytotoxicity of fast neutrons in a murine lymphoma cell line.** *Can J Physiol Pharmacol* 2004;82:140-5.
8. Deplanque G., Ceraline J., Lapouge G., Dufour P., Bergerat J.P., Klein-soyer C. **Conflicting effects of caffeine on apoptosis and clonogenic survival on human K thyroid carcinoma cell lines with different p53 status after exposure to cisplatin or Uvc irradiation.** *Biochem Biophys Res Commun* 2004;314:1100-6.
9. Ceraline J., Cruchant M.D., Erdmann E., Erbs P., Kurtz J.E., Duclos B., Jacqmin D., Chopin D., Bergerat J.P. **Constitutive activation of the androgen receptor by a point mutation in the hinge region : a new mechanism for androgen-independent growth in prostate cancer.** *Int J Cancer* 2004;108:152-7.
10. Ceraline J., Deplanque G., Noel F., Natarajan-ame, Bergerat J.P., Klein-soyer C. **Sensitivity to cisplatin treatment of human K1 thyroid carcinoma cell lines with altered p53 function.** *Cancer Chemother Pharmacol* 2003;51:91-95.
11. Fischer B., Coelho D., Dufour P., Bergerat J.P., Denis J.M., Gueulette J., Bischoff P. **Caspase-8-mediated BID cleavage in p53-dependent apoptosis.** *Biochem Biophys Res Comm* 2003;306:516-522.
12. Ganansia-Leymarie V., Bischoff P., Bergerat J.P., Holl V. **Signal transduction pathways of taxanes-induced apoptosis.** *Curr Med Chem Anti-Canc Agents* 2003;3:291-306.
13. Ceraline J., Erdmann E., Erbs P., Deslandres-Cruchant M., Jacqmin D., Duclos B., Klein-soyer C., Dufour P., Bergerat J.P. **A yeast-based functional assay for the detection of the mutant androgen receptor in prostate cancer.** *Eur J Endocrinol* 2003;148:99-110.
14. Gandillet A., Alexandre E., Holl V., Royer C., Bischoff P., Cinqualbre J., Wolf P., Jaeck D., Richert L. **Hepatocyte ploidy in normal young rat.** *Comp Biochem Physiol A* 2003;134:665-673.
15. Mah-Becherel M.C., Céraline J., Deplanque G., Chenard M.P., Bergerat J.P., Cazenave J.P., Klein-soyer C. **Anti-Angiogenic Effects of the Thienopyridine SR 25989 in Vitro and in Vivo in a Murine Pulmonary Metastasis Model.** *Br J Cancer* 2002;86:803-10.
16. Coehlo D., Fischer B., Holl V., Dufour P., Denis J.M., Gueulette J., Bergerat J.P., Bischoff P. **Induction of apoptosis by high linear energy transfer radiation : role of p53.** *Can J Physiol Pharmacol* 2002;80:644-649.
17. Redon R., Hussenet T., Bour G., Caulee K., Jost B., Muller D., Abecassis J., Du Manoir S. **Amplicon mapping and transcriptional analysis pinpoint cyclin L as a candidate oncogene in head and neck cancer.** *Cancer Res* 2002;62:6211-6217.
18. Hyun J.W., Holl V., Weltin D., Dufour P., Luu B., Bischoff P. **Effects of combinations 7β-hydroxycholesterol and anticancer drugs or ionizing radiation on the proliferation of cultured tumor cells.** *Anticancer Res* 2002;22:943-948.
19. Herrbrecht R., Letscher-Bru V., Oprea C., Lioure B., Waller J., Campos F., Villard O., Liu K.L., Natarajan-ame, Lutz S., Dufour P., Bergerat J.P., Candolfi E. **Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients.** *J Clin Oncol* 2002;20(7):1898-1906.
20. Coehlo D., Fischer B., Holl V., Jung G.m., Dufour P., Bergerat J.P., Denis J.M., Gueulette J., Bischoff P. **Involvement of TP53 in Apoptosis Induced in Human Lymphobalstoid Cells by Fast Neutrons.** *Radiat Res* 2002;157:446-452.
21. Limacher J.M., Girard-Lemaire F., Jeandidier E., Chenard-Neu M.P., Kassem M., Flori E., Bergerat J.P. **Gastrointestinal stromal tumor in an XYY/XY male.** *Cancer Genet Cytogenet* 2002;133:152-155.
22. Limacher J.M., Frebourg T., Natarajan-ame, Bergerat J.P. **Two metachronous tumours in the radiotherapy fields of a patient with Li-Fraumeni syndrome.** *Int J Cancer* 2001;96:238-242.
23. Deplanque G., Céraline J., Mah-Becherel M.C., Chenard M.P., Cazenave J.P., Bergerat J.P., Klein-soyer C. **Caffeine and the G2/M block override : a concept resulting from a misleading cell kinetic delay independently of functional p53.** *Int J Cancer* 2001;94:363-369.
24. Deplanque G., Céraline J., Mah-Becherel M.C., Cazenave J.P., Bergerat J.P., Klein-soyer C. **Caffeine and the G2/M Block Override : A Concept Resulting from a Misleading Cell Kinetic Delay, Independent of Functional P53.** *Int J Cancer* 2001;94:363-9.

25. Holl V., Coelho D., Dufour P., Bergerat J.P., Denis J.M., Gueulette J., Bischoff P. **Induction de l'apoptose dans des lymphocytes spléniques de souris par un faisceau d'ions lourds.** *Can. J. Physiol. Pharmacol.* 2001;79:109-113.
26. Holl V., Coelho D., Dufour P., Denis J.M., Florentin I., Mathieu J., Gueulette J., Bischoff P. **Induction de l'Apoptose chez des Lymphocytes Spléniques de Souris par les Ions Lourds du Ganil.** *Can J Physiol Pharmacol* 2001;79:109-113.
27. Redon R., Muller D., Caulee K., Wanherdrick K., Abecassis J., Du Manoir S. **A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas. PIK3CA but not p63 gene as a likely target of 3q26-qter gains.** *Cancer Res* 2001;61:4122-4129.
28. Vincent F., Céraline J., Goldblum S., Klein-soyer C., Bergerat J.P. **A new method to follow DNA gap filling during nucleotide excision repair of UVc-induced damage by flow cytometry.** *Cytometry* 2001;45:96-101.
29. Vincent F., Ceraline J., Goldblum S., Klein-soyer G., Bergerat J.P. **A New Flow Cytometric Method to Follow DNA Gap Filling during Nucleotide Excision Repair of UVc-Induced Damage.** *Cytometry* 2001;45:96-101.
30. Milon R., Muller D., Schultz I., Salvi R., Ghanassia J.P., Frebourg T., Wasylyk B., Abecassis J. **Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance.** *Oral Oncol* 2001;37:620-631.
31. Guitard E., Parker F., Millon R., Abecassis J., Tocque B. **G3BP is overexpressed in human tumors and promotes S phase entry.** *Cancer Lett* 2001;162:213-221.
32. Bischoff P., Holl V., Coelho D., Weltin D., Marchal J. **Induction of apoptosis in murine spleen cells by a gamma irradiation delivered at low-dose rate.** *Soumis à Radiation and Environmental Biophysics* 2001
33. Fricker J.P., Muller D., Cutuli B., Rodier J.F., Janser J.C., Jung G.m., Mors R., Petit T., Haegele P., Abecassis J. **Germ-line mutations of the BRCA1 gene in northeastern France.** *Bull Cancer* 2000;87:739-744.
34. Coelho D., Holl V., Weltin D., Lacomberie T., Magnenet P., Dufour P., Bischoff P. **Caspase-3-like activity determines the type of cell death following ionizing radiation.** *Br. J. Cancer* 2000;83:642-649.
35. Deplanque G., Vincent F., Mah-Becherel M.C., Cazenave J.P., Bergerat J.P., Klein-soyer C. **Caffeine does not cause override of the G2/M block induced by UVc or gamma radiation in normal human skin fibroblasts.** *Br. J. Cancer* 2000;83:346-353.
36. Mirjole J.F., Barberi-Heyob M., Didelot C., Peyrat J.P., Abecassis J., Millon R., Merlin J.L. **Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.** *Br J Cancer* 2000;83:1380-1386.
37. Bischoff P., Holl V., Coelho D., Dufour P., Luu B., Weltin D. **Apoptosis at the interface of immunosuppressive and anti-cancer activities: the examples of alkylating agents and oxysterols.** *Curr. Med. Chem.* 2000;7(7):693-713.
38. Holl V., Coelho D., Silbernagel L., Keyser J.F., Waltzinger C., Dufour P., Bischoff P. **Prevention of nitrogen mustard-induced apoptosis in normal and transformed lymphocytes by ebselen.** *Biochem. Pharmacol.* 2000;60(11):1565-1577.
39. Charbonnier F., Raux G., Wang Q., Drouot N., Cordier F., Limacher J.M., Saurin J.C., Puisieux A., Olschwang S., Frebourg T. **Detection of exon deletions and duplications of the mismatch repair genes in hereditary nonpolyposis colorectal cancer families using multiplex polymerase chain reaction of short fluorescent fragments.** *Cancer Res* 2000;60:2760-2763.
40. Holl V., Coelho D., Weltin D., Hyun J.W., Dufour P., Bischoff P. **Modulation of the antiproliferative activity of anticancer drugs in hematopoietic tumor cell lines by the poly(ADP-ribose)polymerase inhibitor 6(5H)-phenanthridinone.** *Anticancer Res* 2000;20(5A):3233-3241.
41. Klein-soyer C., Azorsa D.O., Cazenave J.P., Lanza F. **CD9 participates in endothelial cell migration during in vitro wound repair.** *Arterioscl Thromb Vasc Biol* 2000;20:360-369.
42. Holl V., Jung P., Weltin D., Dauvergne J., Burger A., Coelho D., Dufour P., Aubertin A.M., Bischoff P., Biellmann J.F. **Evaluation of the antitumoral properties of 1-(3'-C-ethynyl-B-D-ribofuranosyl)Uracil (PJ272), a recent ribo-nucleoside analogue.** *Anticancer Res.* 2000;20:1739-1742.
43. Ganguli G., Abecassis J., Wasylyk B. **MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis.** *EMBO J* 2000;19:5135-5147.
44. Holl V., Coelho D., Weltin D., Denis J.M., Dufour P., Gueulette J., Bischoff P. **Ex-vivo determination of the effect of whole body exposure to fast neutrons on murine spleen cell viability and apoptosis.** *Radiat. Res* 2000;154(3):301-306.
45. Kurtz J.E., Deplanque G., Borel C., Mathelin C., Prévost G., Poulin G., Barats J.C., Bergerat J.P., Chapelle-Marcillac I., Bardonnnet M., Dufour P. **Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer.** *Ann. Oncol.* 2000;11:229-230.
46. Bischoff P., Holl V. **Radiation-induced apoptosis in cancer cells.** *BioValley Newsletter* 20002.
47. Holl V. **Apoptose induite par la chlorméthine et les radiations ionisantes dans les lymphocytes normaux et tumoraux : rôle de la caspase-3.** *Thèse de doctorat de l'Université Louis Pasteur de Strasbourg* 2000
48. Vincent F., Deplanque G., Céraline J., Duclos B., Bergerat J.P. **p53-independent regulation of cyclin B1 in normal human fibroblasts during UV-induced G2-arrest.** *Biol* 1999;91:665-674.
49. Hamid D., Duclos B., Barats J.C., Prevot G., Hummel M., Baldauf J.J., Brettes P., Giron C., Maloisel F., Lioure B., Herbrecht R., Audhuy B., Bergerat J.P., Oberling F., Dufour P. **Prognostic factors in ovarian carcinoma in complete histologic remission at second-look surgery.** *Int J Gynecol Cancer* 1999;9:231-237.

50. Millon R., Jacqmin D., Muller D., Guillot J., Eber M., Abecassis J. **Detection of prostate-specific antigen or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients : clinical implications.** *Eur Urol* 1999;39:278-285.
51. Bonnetterre J., Spielman M., Guastalla J.P., Marty M., Viens P., Chollet P., Roche H., Fumoleau P., Mauriac L., Bourgeois H., Namer M., Bergerat J.P., Misset J.L., Trandafir L., Mahjoubi M. **Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.** *Eur. J* 1999; 35:1431-1439.
52. Wasyluk C., Salvi R., Argentini M., Dureuil C., Delumean I., Abecassis J., Debussche L., Wasyluk B. **p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53.** *Oncogene* 1999;18:1921-34.
53. Escudier B., Chevreau C., Lasset C., Douillard J.Y., Ravaud A., Fabbro M., Caty A., Rossi J.F., Viens P., Bergerat J.P., Savary J., Negrier S. **Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérapie.** *J. Clin. Oncol* 1999;17:2039-2043.
54. Kurtz J.E., Deplanque G., Duclos B., Eichler F., Giron C., Limacher J.M., Herbrecht R., Maloïsel F., Oberling F., Bergerat J.P., Dufour P. **Paclitaxel-anthracycline combination chemotherapy in relapsing advanced ovarian cancer after platinum-based chemotherapy: a pilot study.** *Gynecol. Oncol* 1998;70:414-417.
55. Massard G., Eichler F., Gasser B., Bergerat J.P., Wihlm J.M. **Recurrence of the mediastinal growing teratoma syndrome.** *Ann. Thorac. Surg* 1998;66:605-606.
56. Cutuli B., Petit T., Hoffstetter S., Velten M., Dufour P., Giron C., Lederlin P., Jung G.m., Bergerat J.P., Maloïsel F., Bey P., Oberling F. **Treatment of subdiaphragmatic Hodgkin's disease: long-term results and side effects.** *Oncol. Rep* 1998;5: 1513-1518.
57. Céraline J., Deplanque G., Duclos B., Limacher J.M., Hajri A., Noël F., Orvain C., Frebourg T., Bergerat J.P. **Inactivation of p53 in normal human fibroblasts increases G2/M arrest and sensitivity to DNA damaging agents.** *Int. J* 1998; 30 (75):432-438.
58. Hugel B., Weltin D., Holl V., Marchal J., Dufour P., Freyssinet J.M., Bischoff P.L. **Assessment of apoptosis occurring in spleen cells from nitrogen mustard-treated or gamma-irradiated mice.** *Anticancer Res* 1998;18:3289-3294.
59. Klein-soyer C., Céraline J., Orvain C., De La Salle C., Bergerat J.P., Cazenave J.P. **Angiogenesis inhibitor SR 25989 upregulates thrombospondin-1 expression in human vascular endothelial cells and foreskin fibroblasts.** *Biol. Cell* 1997;89: 295-307.
60. Céraline J., Deplanque G., Duclos B., Limacher J.M., Vincent F., Goldblum S., Bergerat J.P. **Relations entre induction de p53, arrêt du cycle cellulaire et survie de fibroblastes humains normaux après agressions génotoxiques.** *Bull* 1997;84: 1007-1016.
61. Wihlm J., Limacher J.M., Levêque D., Duclos B., Dufour P., Bergerat J.P., Methlin G. **Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients.** *Bull* 1997;84:603-608.
62. Guriec N., Gairard B., Marcellin L., Wilk A., Caldéroli H., Renaud R., Bergerat J.P., Oberling F. **CD44 isoforms with exon v6 and metastasis of primary N0M0 breast carcinomas.** *Breast Cancer Res. Tr* 1997;44:261-268.
63. Klein-soyer C., Duhamel-Clerin E., Ravanat C., Orvain C., Lanza F., Cazenave J.P. **PF4 inhibits thrombin stimulated MMP-1 and MMP-3 metalloproteinase expression in human vascular endothelial cells.** *Cr. Acad. Sci* 1997;320:857-868.
64. Teh B.T., Giraud S., Sari N.F., Hii S.I., Bergerat J.P., Larsson C., Limacher J.M., Nicol D. **Familial non-VHL non-papillary clear-cell renal cancer.** *Lancet* 1997;22(349):848-849.
65. Duhamel-Clerin E., Orvain C., Lanza F., Cazenave J.P., Klein-soyer C. **Thrombin receptor- mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells.** *Arteroscl. Throm. Vas* 1997;17:1931-1938.
66. Stoppa-Lyonnet D., Fricker J.P., Essieux L., Pages S., Limacher J.M., Sobol H., Laurent-Puig P., Thomas G. **Segregation of two BRCA Mutations in a single family.** *Am. J. Hum* 1996;59:479-481.
67. Mauillon J.L., Michel P., Limacher J.M., Latouche J.B., Dechelotte P., Charbonnier F., Martin C., Moreau V., Metayer J., Paillot B., Frebourg T. **Identification of novel germline hMLH1 mutations including a 22 kb Alu-mediated deletion in patients with familial colorectal cancer.** *Cancer Res* 1996;56:5728-5733.
68. Guriec N., Marcellin L., Gairard B., Caldéroli H., Wilk A., Renaud R., Bergerat J.P., Oberling F. **E-cadherin mRNA expression in breast carcinomas correlates with overall and disease-free survival.** *Invas. Metast* 1996;16:19-26.
69. Guriec N., Marcellin L., Gairard B., Caldéroli H., Wilk A., Renaud R., Bergerat J.P., Oberling F. **CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma.** *Clin. Exp. MétaStasis* 1996;14:434-439.
70. Flaman J.M., Waridel F., Estreicher A., Vannier A., Limacher J.M., Gilbert D., Iggo R., Frebourg T. **The human tumour suppressor gene p53 is alternatively spliced in normal cells.** *Oncogène* 1996;12:813-818.
71. Flaman J.M., Frebourg T., Moreau V., Charbonnier F., Chappuis P., Spaino A.P., Limacher J.M., Bron L., Benhattar J., Tada M., Estreicher A., Iggo R.D. **A simple p53 fonctionnal essay for screening cell lines, blood and tumours.** *P.N.A.S* 1995;92:3963-3967.
72. Sobol H., Birnbaum D., Eisinger F., Chamouton V., Frenay M., Gesta P., Jaquemier J., Limacher J.M., Longuy M., Lortholary A., Nagues C., Vennin P., Sauvan R., Schraub S. **Aspects génétiques des cancers du sein.** *Références en Gynécologie Obstétrique* 1995;3:182-192.
73. Lalle P., Stoppa-Lyonnet D., Mazoyer S., Rio P., Girodet C., Hardouin A., Narod S.A., Sobol H., Bignon Y.J., Limacher J.M. **Prédisposition héréditaire aux cancers du sein et de l'ovaire.** *Bull. Cancer* 1993;80:857-865. avec le Groupe Génétique et Cancers de la FNCLCC.